| Literature DB >> 35245435 |
Sarah Naomi Olsen1, Laura Godfrey1, James P Healy1, Yoolim A Choi1, Yan Kai1, Charles Hatton1, Florian Perner2, Elena L Haarer1, Behnam Nabet3, Guo-Cheng Yuan4, Scott A Armstrong5.
Abstract
MLL rearrangements produce fusion oncoproteins that drive leukemia development, but the direct effects of MLL-fusion inactivation remain poorly defined. We designed models with degradable MLL::AF9 where treatment with small molecules induces rapid degradation. We leveraged the kinetics of this system to identify a core subset of MLL::AF9 target genes where MLL::AF9 degradation induces changes in transcriptional elongation within 15 minutes. MLL::AF9 degradation subsequently causes loss of a transcriptionally active chromatin landscape. We used this insight to assess the effectiveness of small molecules that target members of the MLL::AF9 multiprotein complex, specifically DOT1L and MENIN. Combined DOT1L/MENIN inhibition resembles MLL::AF9 degradation, whereas single-agent treatment has more modest effects on MLL::AF9 occupancy and gene expression. Our data show that MLL::AF9 degradation leads to decreases in transcriptional elongation prior to changes in chromatin landscape at select loci and that combined inhibition of chromatin complexes releases the MLL::AF9 oncoprotein from chromatin globally.Entities:
Keywords: DOT1L inhibition; MENIN inhibition; MLL-fusions; epigenetics; gene regulation; leukemia; targeted protein degradation
Mesh:
Substances:
Year: 2022 PMID: 35245435 PMCID: PMC9044330 DOI: 10.1016/j.molcel.2022.02.013
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 19.328